Dexmedetomidine Wound Infiltration in Cesarean Section

• Status: Active, not recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

The effects of four different wound infiltration protocols in cesarean section will be investigated on parturient' pain intensity, PCA morphine consumption given, side effects and parturient' overall satisfaction.

One group will receive for wound infiltration dexmedetomidine, the second ropivacaine, the third dexmedetomidine combined with ropivacaine, while the last one will receive normal saline (placebo group).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Attikon Hospital
• Treatments: Dexmedetomidine; Ropivacaine

Criteria

Inclusion Criteria:

• pregnancy >37 weeks, ASA I-II, BMI<35

Exclusion Criteria:

• patient refusal, epilepsy, GERD, morbid obesity, drug allergy, ASA class >2, presence of atrioventricular block, severe systemic disease, multiple gestation, high risk pregnancy, contraindications to epidural technique, a history of severe systemic disease, recreational drug or alcohol use